Samik Pharm Co

Samik Pharm Co EBITDA per Employee

EBITDA per Employee of Samik Pharm Co (014950.KQ) as of Oct 27, 2026.

EBITDA per Employee

-KRW

Last updated:

EBITDA per Employee of Samik Pharm Co is 2026 - KRW. EBITDA per Employee of Samik Pharm Co was 2025 - KRW. It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Samik Pharm Co Stock analysis

What does Samik Pharm Co do? Samik Pharm Co Ltd manufactures and sells pharmaceutical products including Cesar Plus tablets for circulatory system treatments, Eravix tablets, Griffin tablets for diabetes, Gluemser tablets, Samik Pharmotidine tablets for digestive issues, Rebacode tablets, Tamitrasemi tablets, and Seklfen tablets as antipyretic anti-inflammatory drugs. The company also produces medications for treating acute vaginal candidiasis, motion sickness in children, and alopecia. Products are sold domestically in Korea and internationally. The firm's revenue comes from the sale of these branded pharmaceutical products to healthcare providers and pharmacies in both domestic and international markets. Key product lines include cardiovascular, diabetes, digestive health, and anti-inflammatory treatments, alongside specialized medications for specific conditions like vaginal candidiasis and motion sickness. The company targets healthcare professionals and consumers seeking treatment for these medical conditions through its domestic and global distribution channels. Samik Pharm Co Ltd's business model relies on the manufacturing and global distribution of its branded pharmaceutical products. The company focuses on delivering targeted treatments for circulatory, diabetes, digestive, and inflammatory conditions, as well as specialized solutions for vaginal candidiasis, motion sickness, and alopecia. Its products are marketed to healthcare providers and end consumers across Korea and overseas markets, generating revenue through direct sales and distribution agreements. Samik Pharm Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Samik Pharm Co stock

On Eulerpool you can find the complete historical development of EBITDA per Employee Samik Pharm Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Samik Pharm Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Samik Pharm Co

All Key Metrics — Samik Pharm Co